Aktis Oncology and Eli Lilly Collaborate to Discover and Develop Novel Anticancer Radiopharmaceuticals
Shots:
- Aktis & Eli Lilly have signed a multi-target discovery collaboration agreement to develop anticancer radiopharmaceuticals, combining Aktis’ miniprotein technology platform & Lilly’s knowledge in drug development & commercialization for solid tumors
- Aktis will obtain $60M upfront in cash & equity investment, $1.1B preclinical, clinical, regulatory & commercial milestones plus tiered royalties. Lilly gains global rights to develop radiopharmaceutical therapeutic & diagnostic products for selected targets
- Furthermore, Aktis keeps full rights to its 7 programs incl. a clinical-stage Nectin-4 target & will handle discovery through initial human imaging while Lilly will handle global clinical development & commercialization, starting from P-I
Ref: Aktis Oncology | Image: Aktis Oncology
Related News:- Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
